How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

Table 1 HTA reports analyzed

	NICE (GB)	ICER (US)	CADTH (CA)	SMC (GB)	AIFA (IT)	HAS (FR)	G-BA (DE)	AEMPS (ES)
Kymriah DLBCL	X			X	X	X	X	X
Kymriah ALL	X	X			X	X	X	X
Yescarta	X	X		X	X	X	X	X
Luxturna	X	X	X	X		X	X	X
Strimvelis	X
Imlygic	X						X	X
Alofisel	X					X	X	X
Provenge	X						X
Glybera						X	X
Zolgensma	X	X	X	X	X	X	X

Key: AEMPS Agencia Española de Medicamentos y Productos Sanitarios, AIFA Agenzia Italiana del Farmaco, ALL acute lymphoblastic leukemia, CADTH Canadian Agency for Drugs and Technologies in Health, DLBCL diffuse large B-cell lymphoma, G-BA Gemeinsamer Bundesausschuss, HAS Haute Autorité de Santé, ICER Institute for Clinical and Economic Review, NICE National Institute for Health and Clinical Excellence, SMC Scottish Medicines Consortium

ISSN: 1472-6963